Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Works matching AU Rodríguez-Cueto, Carmen
Results: 16
1
2
Targeting glial cannabinoid CB<sub>2</sub> receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
3
Prospects for cannabinoid therapies in basal ganglia disorders.
- Published in:
- 2011
- By:
- Publication type:
- journal article
4
Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia.
- Published in:
- Antioxidants, 2024, v. 13, n. 9, p. 1072, doi. 10.3390/antiox13091072
- By:
- Publication type:
- Article
5
Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis.
- Published in:
- Brain Pathology, 2021, v. 31, n. 6, p. 1, doi. 10.1111/bpa.12972
- By:
- Publication type:
- Article
6
Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias.
- Published in:
- Pathobiology, 2014, v. 81, n. 3, p. 149, doi. 10.1159/000358127
- By:
- Publication type:
- Article
7
BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 22, p. 12533, doi. 10.3390/ijms222212533
- By:
- Publication type:
- Article
8
Targeting the CB<sub>2</sub> receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis.
- Published in:
- British Journal of Pharmacology, 2021, v. 178, n. 6, p. 1373, doi. 10.1111/bph.15386
- By:
- Publication type:
- Article
9
Changes in CB<sub>1</sub> and CB<sub>2</sub> receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.
- Published in:
- British Journal of Pharmacology, 2014, v. 171, n. 6, p. 1472, doi. 10.1111/bph.12283
- By:
- Publication type:
- Article
10
Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.
- Published in:
- 2014
- By:
- Publication type:
- journal article
11
Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.
- Published in:
- PLoS ONE, 2017, v. 12, n. 4, p. 1, doi. 10.1371/journal.pone.0176521
- By:
- Publication type:
- Article
12
Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets.
- Published in:
- Frontiers in Molecular Neuroscience, 2019, p. N.PAG, doi. 10.3389/fnmol.2019.00094
- By:
- Publication type:
- Article
13
Targeting Cannabinoid CB<sub>2</sub> Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.
- Published in:
- Frontiers in Neuroscience, 2016, p. 1, doi. 10.3389/fnins.2016.00406
- By:
- Publication type:
- Article
14
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.
- Published in:
- Journal of Neuroinflammation, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12974-023-02792-z
- By:
- Publication type:
- Article
15
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis.
- Published in:
- Molecules, 2021, v. 26, n. 24, p. 7643, doi. 10.3390/molecules26247643
- By:
- Publication type:
- Article
16
Editorial: Cannabinoids as potential treatment for neurological diseases.
- Published in:
- Frontiers in Neuroscience, 2022, v. 16, p. 1, doi. 10.3389/fnins.2022.1108101
- By:
- Publication type:
- Article